Dexcom (DXCM) Q3 2025 10-Q Quarterly Report
Filed: Oct 30, 2025Period ending Sep 30, 2025
Health Care
Surgical & Medical Instruments & ApparatusSEC EDGAR Dexcom (DXCM) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Oct 30, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Dexcom Q3 2025 10-Q Analysis
Management Discussion & Analysis
- • Revenue $1.21B in Q3 2025, up 22% YoY from $994.2M in Q3 2024
- • Operating margin 20.0% vs 15.3% YoY; net income margin 23.5% vs 13.5% YoY; net income $283.8M up 111% YoY
- • Best segment: US revenue $851.9M up 21% YoY; worst: Reusable Hardware revenue down to 3% of total revenue from 4% YoY
- • Cash, cash equivalents, and short-term securities $3.32B at quarter-end; operating cash flow $659.9M, up 231% YoY
- • Near-term outlook: management highlights continued customer growth, pricing headwinds, and expects cash from operations sufficient for core business funding
Risk Factors
- • No newly added risk factors this quarter; risk section supplements and supersedes 2024 10-K disclosures
- • No material changes to previously disclosed risk factors; risks remain consistent with 2024 10-K filing
- • Ongoing regulatory risk related to product approvals and compliance impacting market access and launch timing
- • Operational risk around supply chain disruptions affecting near-term production and delivery schedules
- • Financial risk includes currency exposure from international sales impacting revenue translation and margins
Dexcom Q3 2025 Quarterly FinancialsXBRL
Revenue
$1.2B
▲ +21.6% YoY▲ +4.5% QoQ
Net Income
$284M
▲ +110.8% YoY▲ +57.8% QoQ
Gross Margin
60.5%
▲ +75bp YoY▲ +95bp QoQ
Operating Margin
20.1%
▲ +476bp YoY▲ +168bp QoQ
Net Margin
23.5%
▲ +993bp YoY▲ +793bp QoQ
ROE
10.4%
Total Assets
$7.5B
EPS (Diluted)
$0.71
▲ +115.2% YoY▲ +61.4% QoQ
Operating Cash Flow
$660M
▲ +230.8% YoY▲ +117.8% QoQ
Source: XBRL data from Dexcom Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Other Dexcom Quarterly Reports
Get deeper insights on Dexcom
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.